Nicola Ryan

Nicola Ryan provides her take on the results of TAILORED-CHIP presented by Duk-Woo Park at the ESC Congress 2025 in Madrid.

Stay updated with the latest in interventional cardiology at #ESCCongress 2025!

This analysis from the XIENCE Short DAPT programme compared the safety and efficacy of one-month versus three-month DAPT in high-bleeding risk patients with and without diabetes mellitus (DM) following PCI with everolimus eluting stents (EES).

This prespecified analysis of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME 3) trial examined the impact on cardiovascular outcomes of treatment by CABG versus FFR-guided PCI in patients with three vessel disease (3-VD), stratified by acute (NSTEMI) or chronic coronary syndrome (CCS) presentation.

This exploratory analysis from the MASTER DAPT trial evaluates the effect of abbreviated versus prolonged DAPT on total ischaemic and bleeding events in high-bleeding-risk patients from the MASTER DAPT trial.

This large retrospective analysis using data from the Republic of Korea’s Nationwide Health Claims database showed that co-prescription of a PPI in patients treated with DAPT following an AMI was associated with reduced major GI bleeding as well as reduced minor GI bleeding requiring hospitalisation, regardless...

This session addresses the management of high thrombus burden in STEMI patients. It reviews available tools and strategies for thrombus management, presents multiple case-based discussions illustrating treatment decisions, and explores the evolving role of thrombus aspiration in contemporary practice.

An 87-year-old female patient, at high bleeding risk and with preserved LV function, presented 2 months ago with an inferior STEMI and multivessel disease. She initially underwent RCA PCI followed by staged LCx PCI. She was now referred for PCI of a long, heavily calcified lesion...

Examine coronary stent loss complications and retrieval techniques in this session. Review innovative approaches such as retrieval of dislodged stents from unusual locations like the renal artery, and discussions on navigating stent-related struggles, including the mechanical journey and consequences of stent loss during PCI.

This session highlights the power of multimodality imaging and physiology in diagnosing MINOCA. Topics include detecting hidden plaque vulnerability, managing unexpected diagnoses beyond MINOCA, decision-making on stenting, AI's added value, and lessons from recurrent cases.

Nicola Ryan and Flavio Ribichini explore the complexities of calcified left main stem disease, emphasizing the critical role of intracoronary imaging in improving patient outcomes. They discuss the practical use of mechanical circulatory support and debate stenting strategies, offering expert insights on when single or dual...

Nicola Ryan explores the fundamentals of an upfront two-stent strategy in bifurcation PCI with Dejan Milasinovic. When the side branch shows significant, high-grade stenosis or extensive disease, direct treatment—via POBA, DCB, or a second stent—may be preferred. Anatomy guides the decision between provisional and two-stent strategies,...

Nicola Ryan provides her take on the WARRIOR trial which was presented by Eileen Handberg at ACC.25 in Chicago.

The manuscript for this trial has not been published and all assumptions are based upon the presentation.

The authors hypothesized that enriching invasive coronary angiography (ICA) with an advanced invasive diagnosis (AID) strategy would increase the diagnostic yield of obstructive and non-obstructive coronary artery disease (INOCA).

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25

NIRS-IVUS offers precise assessment of coronary artery pathology but is invasive and limited in scope, while CCTA is emerging as a non-invasive alternative for comprehensive plaque evaluation.

The AD-HOC Registry aimed to evaluate procedural success and clinical outcomes of current-generation BEVs and SEVs in treating stenotic Sievers type 1 BAV.

The TCW trial found that FFR-guided PCI with TAVI offers favorable one-year outcomes, including lower rates of all-cause mortality, MI, disabling stroke, revascularisation, valve reintervention, and severe bleeding, compared to CABG with SAVR.

Dear Colleagues, dear PCR Companions,

As we welcome a new year, it is the perfect time to reflect on what we achieved together over the past year—both as a celebration of our successes and as motivation to continue improving in the year ahead.

2024 was a record year...

The present study compares a novel sirolimus-coated balloon with a clinically proven paclitaxel-coated balloon for the treatment of de novo coronary lesions, demonstrating non-inferiority in terms of angiographic late lumen loss at 6 months.

This registry-based observational study demonstrated that, in patients with STEMI and LTB, TA failure was associated with reduced myocardial perfusion and increased all-cause and cardiovascular mortality.

Join this roundtable discussion with Nicola Ryan and José Antonio Baz Alonso as they delve into the Empire One trial outcomes. Learn about the IMPERIA™ delivery system for the ALLEGRA™ heart valve, its unique features, and trial results, including detailed hemodynamic findings. Hear insights on its...

This study aims to evaluate changes in microcirculatory function post-TAVI, specifically assessing resting and hyperaemic absolute coronary flow and microvascular resistance before TAVI, immediately post, and at 6-month follow-up.

The aim of this pre-specified analysis of the ILUMIEN IV trial was to assess the relationship between post-PCI OCT parameters of suboptimal stent implantation and clinical outcomes.

In this analysis, the 3-year outcomes of the TRILUMINATE study are presented, evaluating the long-term effectiveness of the TriClip T-TEER system on TR reduction, right ventricular remodeling, quality of life, and heart failure symptoms.

Nicola Ryan provides her take on the ECLIPSE trial presented by Ajay J. Kirtane at TCT 2024 in Washington.

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

What was new and hot in interventional cardiology at #ESCCongress 2024!

This trial found that, in ACS patients undergoing PCI, DP-DES and BP-DES had similar patient-oriented outcomes at three years, but BP-DES had higher device-oriented composite outcomes, mainly due to increased TLR risk.